查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615370

真菌感染疾病诊断市场：按类型、诊断方法、最终用户划分 - 全球预测 2025-2030

Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

真菌感染疾病诊断市场2023年估值为20.9亿美元，预计到2024年将达到22.3亿美元，复合年增长率为6.96%，到2030年预计将达到33.5亿美元。

真菌感染疾病诊断市场的范围包括诊断方法，包括分子诊断、免疫诊断和其他传统技术，旨在识别医疗环境中的真菌病原体。由于免疫力缺乏低下患者数量的增加和影响病原体传播的气候变迁等因素，不同人群中真菌感染疾病的发病率不断增加，从而产生了这一需求。最终用途涵盖医院、诊所和实验室，包括医疗服务提供者、研究人员、製药公司等。关键的成长要素包括诊断技术的进步、意识的提高以及政府对感染疾病控制的资助。快速、非侵入性诊断工具的开发以及人工智慧和机器学习的整合用于预测诊断存在潜在的机会。公司应专注于扩大其 POCT（就地检验）能力。 POCT 可以快速诊断，在资源匮乏的地区特别有用。挑战包括先进诊断系统的高成本、发展中地区获得医疗保健的机会有限，以及由于症状与其他疾病重迭而识别真菌病原体的复杂性。创新是可能的，例如便携式诊断技术、用于早期检测的新型生物标记物以及可以提高准确性同时降低人事费用的自动化系统。对阐明真菌抗药性机制和提高现有诊断工具灵敏度的研究可能会进一步推动市场的成熟。目前市场充满活力，生技公司的兴趣日益浓厚，医疗机构与高科技公司之间的合作不断加强，以开发智慧诊断。当公司在这个市场上航行时，他们可能会受益于医学教育的战略重点以及与政府机构和非政府组织合作以提高诊断的可及性。解决负担能力问题并加快新诊断解决方案的核准流程可以缓解限制并加速成长。

主要市场统计
基准年[2023] 20.9亿美元
预测年份 [2024] 22.3亿美元
预测年份 [2030] 33.5亿美元
复合年增长率（%） 6.96%

市场动态：揭示快速发展的真菌感染疾病诊断市场的关键市场洞察

供需的动态交互作用正在改变真菌感染疾病诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 真菌感染疾病的流行和有效诊断方法的需求
    • 政府提高真菌感染疾病管理意识的倡议
    • 真菌传染病检查系列获得有利核准
  • 市场限制因素
    • 真菌感染疾病分子和遗传学诊断的复杂性
  • 市场机会
    • 分子和照护现场诊断技术的进步
    • 远距皮肤科在真菌感染疾病检测和诊断的潜力
  • 市场问题
    • 与诊断方法不准确相关的局限性

波特五力：引领真菌感染疾病诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解真菌感染疾病诊断市场的外部影响

外部宏观环境因素在塑造真菌感染疾病诊断市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解真菌感染疾病诊断市场的竞争格局

对真菌感染疾病诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：真菌感染疾病诊断市场供应商的绩效评估

FPNV定位矩阵是评估真菌感染疾病诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製真菌感染疾病诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，真菌感染疾病诊断市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 真菌感染疾病的流行和有效诊断方法的需求
      • 政府提高真菌感染疾病管理意识的倡议
      • 真菌传染病检查系列核准
    • 抑制因素
      • 真菌感染疾病分子遗传学诊断的复杂性
    • 机会
      • 分子诊断技术和照护现场诊断技术的进展
      • 远距皮肤病学在检测和诊断真菌感染疾病的潜力
    • 任务
      • 与诊断方法不准确相关的局限性
  • 市场区隔分析
    • 类型：由于患者免疫力下降而导致机会性真菌感染疾病的发生率增加
    • 诊断方法：细胞和分子生物学的进步导致采用分子诊断方法来检测感染。
    • 最终用户：不断上涨的医疗成本提高了医院诊断真菌感染疾病的重要性。
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章真菌感染疾病诊断市场：按类型

  • 介绍
  • 地方性真菌感染疾病
  • 机会性真菌感染疾病
  • 皮下真菌感染疾病
  • 表层真菌感染疾病
  • 全身性真菌感染疾病

第七章真菌感染疾病诊断市场：依诊断方法

  • 介绍
  • 抗原测试
  • 皮肤科检查
  • 组织病理学
  • 微生物培养
  • 分子诊断
  • 血清学

第八章真菌感染疾病诊断市场：依最终用户分类

  • 介绍
  • 医院
  • 照护现场
  • 研究所
  • 专科诊所

第九章北美和南美真菌感染疾病诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区真菌感染疾病诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲真菌感染疾病诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 明尼苏达大学研究人员成功测试了治疗真菌性脑膜炎的新抗真菌疗法
    • Applied BioCode 宣布推出研究真菌组合检测
    • 亚利桑那大学的研究人员帮助追踪亚利桑那州污水中的致命真菌
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Associates of Cape COD, Inc. by Seikagaku Group company
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • Eli Lilly and Company
  • ELITech Group
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Immununexpress Inc.
  • IMMY
  • InBios International, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Norgen BIoTek Corp.
  • PerkinElmer, Inc.
  • Polysciences, Inc.
  • Qiagen NV
  • Siemens Healthineers
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-346757DFA1E9

The Fungal Infections Diagnosis Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.23 billion in 2024, and is projected to grow at a CAGR of 6.96%, to USD 3.35 billion by 2030.

The scope of the fungal infections diagnosis market encompasses diagnostic methods, including molecular diagnostics, immunodiagnostics, and other traditional techniques, aimed at identifying fungal pathogens in medical settings. The necessity arises from the rising incidence of fungal infections across various populations, attributed to factors like increasing immunocompromised patients and climate change affecting pathogen spread. Application extends to hospitals, clinics, and laboratories, with end-use scope involving healthcare providers, researchers, and pharmaceutical companies. Key growth influencers include advancements in diagnostic technologies, increasing awareness, and government funding for infectious disease management. Potential opportunities lie in the development of rapid, non-invasive diagnostic tools and the integration of AI and machine learning for predictive diagnostics. Companies should focus on expanding POCT (point-of-care testing) capabilities, which can provide quicker diagnoses and are particularly beneficial in under-resourced regions. Challenges include high costs of advanced diagnostic systems, limited access to healthcare in developing regions, and the complexity of fungal pathogen identification due to overlapping symptoms with other diseases. Innovations can be directed towards portable diagnostic technologies, novel biomarkers for early detection, and automated systems that can enhance accuracy while reducing labor costs. Research on understanding the resistance mechanisms of fungal strains and improving the sensitivity of existing diagnostic tools could further drive market sophistication. The market is currently dynamic, with a growing interest from biotech firms and increasing collaborations between healthcare organizations and tech companies to develop smart diagnostics. As businesses navigate this market, a strategic focus on healthcare education and partnerships with governmental and non-governmental organizations to enhance diagnostic accessibility could be beneficial. Addressing affordability and speeding up approval processes for new diagnostic solutions could mitigate limitations and accelerate growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.35 billion
CAGR (%) 6.96%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fungal Infections Diagnosis Market

The Fungal Infections Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of fungal infections and need for effective diagnosis methods
    • Government initiatives promoting awareness of fungal infection management
    • Favorable approvals for fungal infection test series
  • Market Restraints
    • Complexity of molecular and genetic fungal infection diagnosis
  • Market Opportunities
    • Advancements in molecular and point-of-care diagnosis technologies
    • Potential of teledermatology in fungal infection detection and diagnosis
  • Market Challenges
    • Limitations associated with the inaccuracy of the diagnostic methods

Porter's Five Forces: A Strategic Tool for Navigating the Fungal Infections Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fungal Infections Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fungal Infections Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fungal Infections Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fungal Infections Diagnosis Market

A detailed market share analysis in the Fungal Infections Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fungal Infections Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fungal Infections Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fungal Infections Diagnosis Market

A strategic analysis of the Fungal Infections Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Endemic Fungal Infections, Opportunistic Fungal Infections, Subcutaneous Fungal Infections, Superficial Fungal Infections, and Systemic Fungal Infections.
  • Based on Diagnostic Method, market is studied across Antigen Testing, Dermatological Examination, Histopathology, Microbiological Culture, Molecular Diagnostics, and Serology.
  • Based on End-User, market is studied across Hospitals, Point-of-Care Settings, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
      • 5.1.1.2. Government initiatives promoting awareness of fungal infection management
      • 5.1.1.3. Favorable approvals for fungal infection test series
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
      • 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
    • 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
    • 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fungal Infections Diagnosis Market, by Type

  • 6.1. Introduction
  • 6.2. Endemic Fungal Infections
  • 6.3. Opportunistic Fungal Infections
  • 6.4. Subcutaneous Fungal Infections
  • 6.5. Superficial Fungal Infections
  • 6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

  • 7.1. Introduction
  • 7.2. Antigen Testing
  • 7.3. Dermatological Examination
  • 7.4. Histopathology
  • 7.5. Microbiological Culture
  • 7.6. Molecular Diagnostics
  • 7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Point-of-Care Settings
  • 8.4. Research Institutions
  • 8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
    • 12.3.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
    • 12.3.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. Associates of Cape COD, Inc. by Seikagaku Group company
  • 5. Astellas Pharma Inc.
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. BioMerieux SA
  • 9. Bruker Corporation
  • 10. Danaher Corporation
  • 11. Eli Lilly and Company
  • 12. ELITech Group
  • 13. Eurofins Viracor, LLC
  • 14. F. Hoffmann-La Roche AG
  • 15. Hologic, Inc.
  • 16. Immununexpress Inc.
  • 17. IMMY
  • 18. InBios International, Inc.
  • 19. Laboratory Corporation of America Holdings
  • 20. Merck KGaA
  • 21. Norgen Biotek Corp.
  • 22. PerkinElmer, Inc.
  • 23. Polysciences, Inc.
  • 24. Qiagen N.V.
  • 25. Siemens Healthineers
  • 26. Takeda Pharmaceutical Company Limited
  • 27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOLOGICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023